Mostrar el registro sencillo del ítem

Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study

dc.rights.licenseopenen_US
dc.contributor.authorROUX, Barbara
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
ORCID: 0000-0002-2568-1928
IDREF: 181595710
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMORIVAL, Camille
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorNOIZE, Pernelle
dc.contributor.authorLAROCHE, Marie Laure
dc.date.accessioned2021-11-15T11:12:50Z
dc.date.available2021-11-15T11:12:50Z
dc.date.issued2021-09-24
dc.identifier.issn1473-7167en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/123799
dc.description.abstractEnBACKGROUND: Potentially inappropriate prescriptions (PIPs) in the older population remain a growing public health concern due to the many associated adverse events increasing healthcare service use and health costs. This study aimed to assess the prevalence and direct costs of PIPs in older adults aged ≥65 years in France. METHODS: A population-based cross-sectional study was conducted in 2017 using a representative sample of the French national healthcare reimbursement system database. PIPs were defined using the French REMEDI[e]S tool. Overall reimbursed direct costs and by PIP category were extrapolated to the French older population. RESULTS: The overall PIP prevalence was estimated at 56.7% (95% CI: 56.4-57.0). Medications with an unfavorable benefit/risk ratio had the highest prevalence (34.0%, 95% CI: 33.7-34.3). Direct costs associated with PIPs represented 6.3% of the total reimbursed medication costs in 2017 (€507 million). Drug duplications were the main contributors to these costs (39.2% of the total reimbursed PIP costs, €199 million) and among all PIPs, proton pump inhibitors (>8 weeks) were the most expensive PIPs (€152 million). CONCLUSIONS: PIP prevalence is still high among French older adults, with substantial direct costs. Large-scale interventions targeting the most prevalent and/or costly PIPs are needed to reduce their clinical and economic impacts.
dc.language.isoENen_US
dc.subject.enOlder adults
dc.subject.enPotentially inappropriate prescriptions
dc.subject.enDrug utilization
dc.subject.enMedication cost
dc.subject.enInsurance health reimbursement
dc.subject.enPharmacoepidemiology
dc.title.enPrevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/14737167.2021.1981863en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34525899en_US
bordeaux.journalExpert Review of Pharmacoeconomics & Outcomes Researchen_US
bordeaux.page1-10en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03428816
hal.version1
hal.date.transferred2021-11-15T11:13:03Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Expert%20Review%20of%20Pharmacoeconomics%20&%20Outcomes%20Research&rft.date=2021-09-24&rft.spage=1-10&rft.epage=1-10&rft.eissn=1473-7167&rft.issn=1473-7167&rft.au=ROUX,%20Barbara&BEZIN,%20Julien&MORIVAL,%20Camille&NOIZE,%20Pernelle&LAROCHE,%20Marie%20Laure&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem